AYTU BIOPHARMA, INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
AYTU BIOPHARMA, INC (AYTU) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $10.35 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-09-22
- AYTU BIOPHARMA, INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-09-30 was $9.68.
- AYTU BIOPHARMA, INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-09-30 was $158.09, a 0.16% increase year-over-year.
- AYTU BIOPHARMA, INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2022-09-30 was $157.84, a 1750.41% increase year-over-year.
- AYTU BIOPHARMA, INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2021-09-30 was $8.53.
- AYTU BIOPHARMA, INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2026 was $10.35, a 33.05% decline from fiscal 2025.
- AYTU BIOPHARMA, INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $15.46, a 76.87% decline from fiscal 2024.
- AYTU BIOPHARMA, INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $66.84, a 49.13% decline from fiscal 2023.
- AYTU BIOPHARMA, INC share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $131.39, a 1261.55% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $10.35 10-K · filed 2026-09-22 | ||||
| 2026-03-31 | $8.72 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $9.68 10-Q · filed 2026-02-03 | ||||
| 2025-09-30 | $9.68 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $15.46 10-K · filed 2025-09-23 | ||||
| 2025-03-31 | $17.21 10-Q · filed 2025-05-14 | ||||
| 2024-06-30 | $66.84 10-K · filed 2024-09-26 | ||||
| 2024-03-31 | $186.18 10-Q · filed 2024-05-15 | ||||
| 2023-12-31 | $184.80 10-Q · filed 2024-02-14 | ||||
| 2023-09-30 | $158.09 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $131.39 10-K · filed 2023-10-12 | ||||
| 2023-03-31 | $131.45 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $134.90 10-Q · filed 2023-02-21 | ||||
| 2022-09-30 | $157.84 10-Q/A · filed 2023-02-21 | $7.89 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $9.65 10-K · filed 2022-09-27 | ||||
| 2022-03-31 | $9.16 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | $8.10 10-Q · filed 2022-02-14 | ||||
| 2021-09-30 | $8.53 10-Q · filed 2021-11-15 | ||||
| 2017-03-31 | $3.23 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |